Anne Luetkemeyer, MD
Enriched profileProfessor, Medicine · University of California, San Francisco
Anne Luetkemeyer is Professor, Medicine at University of California, San Francisco. OpenAlex indexes 116 publications with 7,052 citations (h-index 33); ClinicalTrials.gov lists 3 registered studies with this person as an investigator.
Data verified 22 Oct 2026
Overview
Updated 22 Oct 2026
Anne Luetkemeyer, MD, is Professor, Medicine at University of California, San Francisco. The public record shows 116 publications with 7,052 citations (h-index 33), centered on Hepatitis C virus research, HIV/AIDS drug development and treatment, HIV/AIDS Research and Interventions. It also documents an investigator role on 3 registered clinical trials, industry payments reported by 4 companies, 2 NIH-funded awards (2019–2026).
- Most recent indexed publication: 2026 · Clinical infectious diseases
- Top research focus: Hepatitis C virus research
- 3 registered trials on ClinicalTrials.gov
- Open Payments reporting from 4 companies
Generated from the cited public record · current as of 22 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 14 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 69.
Clinical & industry
trials, payments and federal fundingPublic positions
sourced statements on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.ucsf.edu ↗
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 22 Oct 2026
Listed as an investigator on 3 registered studies on ClinicalTrials.gov. The most recent:
- Evaluation of Doxycycline Post-exposure Prophylaxis to Reduce Sexually Transmitted Infections in PrEP Users and HIV-infected Men Who Have Sex With Men
Sponsor: University of California, San Francisco
- A Study of the Safety and Effectiveness of Simeprevir and Sofosbuvir for Patients With HIV and Hepatitis C
Sponsor: University of California, San Francisco
- Entecavir Intensification for Persistent HBV Viremia in HIV-HBV Infection
Sponsor: University of California, San Francisco
Industry payments
Updated 22 Oct 2026
4 companies reported payments to CMS in program years 2023–2025. These are public disclosures, not judgments. The latest:
- Shionogi IncProgram year20252 payments
- ViiV Healthcare CompanyProgram year20251 payment
- Gilead Sciences, Inc.Program year20251 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
29%Aminoketone8.5%Bupropion Xl100%Part D<11 patientsSSRI6.2%Fluoxetine Hcl76%Citalopram Hbr24%Part D<11 patients+ 6 more classes in this area
Cardiovascular
26.8%Statin14.1%Atorvastatin Calcium100%Part D≥12 patientsACE inhibitor7.4%Benazepril Hcl75%Benazepril-Hydrochlorothiazide26%Part D<11 patients+ 2 more classes in this area
Anti-infectives
25.8%Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor10.9%Tivicay52%Dovato33%Juluca15%Part D<11 patientsHuman Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor5.9%Pifeltro100%Part D<11 patients+ 4 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 22 Oct 2026
2 NIH research awards on record, funded 2019–2026 per NIH RePORTER. The latest:
- The Doxy-PEP Impact Study: a multi-city US longitudinal cohort to evaluate doxy-PEP field effectiveness, investigate associated antimicrobial resistance, and establish doxy-PEP to need ratios
University of California, San Francisco
FY2026$1,480,679R01AI181732 - The Doxy-PEP Impact Study: a multi-city US longitudinal cohort to evaluate doxy-PEP field effectiveness, investigate associated antimicrobial resistance, and establish doxy-PEP to need ratios
University of California, San Francisco
FY2025$1,493,206R01AI181732 - The Doxy-PEP Impact Study: a multi-city US longitudinal cohort to evaluate doxy-PEP field effectiveness, investigate associated antimicrobial resistance, and establish doxy-PEP to need ratios
University of California, San Francisco
FY2024$1,628,180R01AI181732
Publications
Updated 22 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Performance Evaluation of the Xpert® HCV Test on Fingerstick Blood in a Prospective Observational Clinical Study at CLIA-Waived Sites in the United States.
Clinical infectious diseases
Article2026 - Ensitrelvir for Covid-19 Postexposure Prophylaxis in Household Contacts.
The New England journal of medicine
Clinical Trial2026 - The Last Mile: Understanding Barriers to Hepatitis C Virus Microelimination Among People with HIV in San Francisco, 2021-2024.
Open forum infectious diseases
Article2026 - Temporal Trends in Hepatitis C Virus Screening and Management in Pregnant Women and Infants Between 2014 and 2024 in San Francisco, California.
The American journal of gastroenterology
Article2026
Most-cited works
by citation count (OpenAlex)- 01Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19Article1,836 citations2020
- 02Timing of Antiretroviral Therapy for HIV-1 Infection and TuberculosisArticle532 citations2011
- 03Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1Article470 citations2015
- 04Postexposure Doxycycline to Prevent Bacterial Sexually Transmitted InfectionsArticle469 citations2023
- 05Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1Article419 citations2015
Network
Updated 22 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 22 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/anne-luetkemeyer-md
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 22 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →infectiousdiseases.ucsf.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →infectiousdiseases.ucsf.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →infectiousdiseases.ucsf.edu ↗
Media & interviews
press, podcasts and appearances- Featured in SF Chronicle article
"Big guns fighting the coronavirus"
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →hividgm.ucsf.edu ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Adil Daud, MD
University of California, San Francisco
Emmanuelle Waubant, MD
University of California, San Francisco
Peter Ganz, MD
University of California, San Francisco
Joel Palefsky, MD
University of California, San Francisco
Thomas Walsh, MD
Cornell University
Vance Fowler, MD
Duke University
Myron Cohen, MD
University of North Carolina at Chapel Hill School of Medicine
Derrick W. Crook
John Radcliffe Hospital